Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets
NCT07486453Phase 1Not yet recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sacubitril + alisartan + amlodipine in primary hypertension (2 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration at 47 days, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 47 days and 2 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
sacubitril + alisartan + amlodipine
03
Conditions
primary hypertension
Beyond the preview
Go deeper on NCT07486453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486453.